Wellcome Leap logo
R3 Global

R3 Global — Execution

Funds global RNA biofoundry collaboration to speed vaccine and biologic development readiness.

ClosedWellcome Leap
View on funder site
About

R3 Global is the international scaling phase of Wellcome Leap's RNA manufacturing program, jointly funded by Wellcome Leap and CEPI (the Coalition for Epidemic Preparedness Innovations) with a combined investment of $60 million. The program's core thesis is that existing batch-production methods for RNA medicines are too slow and expensive to respond to pandemics or reach patients in low-income co…

What this grant funds

Global distributed biofoundry network using continuous-flow manufacturing to produce RNA medicines faster and at lower cost, co-funded by Wellcome Leap and CEPI.

Key facts
CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.One-off
Next deadlineiThe next date applications are due. Rolling means you can apply any time.—
Decision timeiTypical time from the deadline to the funder's decision.—
Project durationiHow long the funded work is expected to run.—
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Cooperative agreement
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.$60M
Funding analytics

Sign up free to see the funding breakdown

Create free accountSign in
Industries

Sign up free to see the industries in scope

Create free accountSign in
Eligibility criteria

Sign up free to see the full eligibility

Create free accountSign in
Last verified: 22 Jul 2026Source: wellcomeleap.org